BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23492738)

  • 21. Novel small molecule therapeutics in rheumatoid arthritis.
    Kelly V; Genovese M
    Rheumatology (Oxford); 2013 Jul; 52(7):1155-62. PubMed ID: 23297340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging therapeutics for rheumatoid arthritis.
    Bingham CO
    Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of peficitinib in rheumatoid arthritis.
    Kaneko Y
    Mod Rheumatol; 2020 Sep; 30(5):773-778. PubMed ID: 32643492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baricitinib (olumiant) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):120-121. PubMed ID: 30036348
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.
    Choy EHS; Miceli-Richard C; González-Gay MA; Sinigaglia L; Schlichting DE; Meszaros G; de la Torre I; Schulze-Koops H
    Clin Exp Rheumatol; 2019; 37(4):694-704. PubMed ID: 30767864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the discovery of selective JAK inhibitors.
    Menet CJ; Rompaey LV; Geney R
    Prog Med Chem; 2013; 52():153-223. PubMed ID: 23384668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK inhibitors for the treatment of rheumatoid arthritis.
    Morinobu A
    Immunol Med; 2020 Dec; 43(4):148-155. PubMed ID: 32501149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis.
    Feist E; Burmester GR
    Rheumatology (Oxford); 2013 Aug; 52(8):1352-7. PubMed ID: 23378664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tofacitinib for the treatment of rheumatoid arthritis.
    Zerbini CA; Lomonte AB
    Expert Rev Clin Immunol; 2012 May; 8(4):319-31. PubMed ID: 22607178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New and future agents in the treatment of rheumatoid arthritis.
    van Vollenhoven RF
    Discov Med; 2010 Apr; 9(47):319-27. PubMed ID: 20423676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK inhibition in inflammatory bowel disease.
    Olivera P; Danese S; Peyrin-Biroulet L
    Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
    Pan Z; Scheerens H; Li SJ; Schultz BE; Sprengeler PA; Burrill LC; Mendonca RV; Sweeney MD; Scott KC; Grothaus PG; Jeffery DA; Spoerke JM; Honigberg LA; Young PR; Dalrymple SA; Palmer JT
    ChemMedChem; 2007 Jan; 2(1):58-61. PubMed ID: 17154430
    [No Abstract]   [Full Text] [Related]  

  • 35. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel therapeutic targets in rheumatoid arthritis.
    Koenders MI; van den Berg WB
    Trends Pharmacol Sci; 2015 Apr; 36(4):189-95. PubMed ID: 25732812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
    Kerrigan SA; McInnes IB
    Curr Rheumatol Rep; 2018 Nov; 20(12):83. PubMed ID: 30406861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baricitinib for the treatment of rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Sep; 12(9):911-9. PubMed ID: 27427830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Gomez-Puerta JA; Mócsai A
    Curr Top Med Chem; 2013; 13(6):760-73. PubMed ID: 23574525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosine kinases as targets in rheumatoid arthritis.
    Tristano AG
    Int Immunopharmacol; 2009 Jan; 9(1):1-9. PubMed ID: 18848912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.